转录延伸机制是胶质母细胞瘤干细胞的药物可及依赖并增强免疫治疗
该研究在患者来源的胶质母细胞瘤干细胞、分化胶质母细胞瘤细胞和神经干细胞中开展基因表达分析和全基因组CRISPR/Cas9筛选,发现YY1与CDK9复合物对胶质母细胞瘤干细胞生存和维持至关重要,靶向该复合物可诱导干扰素反应并增强免疫检查点治疗疗效。
要点
- YY1-CDK9转录延伸复合物是胶质母细胞瘤干细胞的关键依赖。
- 靶向YY1-CDK9可诱导RNA m6A修饰依赖的干扰素反应。
- 靶向YY1-CDK9可减少调节性T细胞浸润并增强免疫检查点治疗疗效。
核心结论
- YY1-CDK9转录延伸复合物定义了胶质母细胞瘤中一个可靶向的细胞状态,该状态具有活跃转录、干扰素反应受抑制和免疫治疗抵抗的特征。
研究设计与样本
- 在大量患者来源的胶质母细胞瘤干细胞、分化胶质母细胞瘤细胞和神经干细胞中开展基因表达分析和全基因组CRISPR/Cas9筛选。
主要发现
- 胶质母细胞瘤干细胞存在RNA聚合酶II介导转录增加的必需转录状态。
- YY1和转录CDK9复合物在体外和体内对胶质母细胞瘤干细胞生存和维持至关重要。
- YY1与CDK9相互作用以调控胶质母细胞瘤干细胞中的转录延伸。
- 遗传或药理学靶向YY1-CDK9复合物可引发RNA m6A修饰依赖的干扰素反应。
- 靶向YY1-CDK9复合物可减少调节性T细胞浸润并增强胶质母细胞瘤中免疫检查点治疗的疗效。
临床怎么用
- YY1驱动的转录延伸机制可作为药物靶点,通过调控m6A修饰程序激活干扰素反应并增强抗PD-1反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma (GBM) is the most lethal primary brain cancer characterized by therapeutic resistance, which is promoted by GBM stem cells (GSC). Here, we interrogated gene expression and whole-genome CRISPR/Cas9 screening in a large panel of patient-derived GSCs, differentiated GBM cells (DGC), and neural stem cells (NSC) to identify master regulators of GSC stemness, revealing an essential transcription state with increased RNA polymerase II-mediated transcription. The YY1 and transcriptional CDK9 complex was essential for GSC survival and maintenance in vitro and in vivo. YY1 interacted with CDK9 to regulate transcription elongation in GSCs. Genetic or pharmacologic targeting of the YY1-CDK9 complex elicited RNA m6A modification-dependent interferon responses, reduced regulatory T-cell infiltration, and augmented efficacy of immune checkpoint therapy in GBM. Collectively, these results suggest that YY1-CDK9 transcription elongation complex defines a targetable cell state with active transcription, suppressed interferon responses, and immunotherapy resistance in GBM. SIGNIFICANCE: Effective strategies to rewire immunosuppressive microenvironment and enhance immunotherapy response are still lacking in GBM. YY1-driven transcriptional elongation machinery represents a druggable target to activate interferon response and enhance anti-PD-1 response through regulating the m6A modification program, linking epigenetic regulation to immunomodulatory function in GBM.This article is highlighted in the In This Issue feature, p. 275.
引用
- Qiu Z, Zhao L, Shen JZ, et al. Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells. Cancer Discov. 2021. PMID: 34615656. doi:10.1158/2159-8290.CD-20-1848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。